Metformin (Glucophage) is a biguanide antidiabetic and the first-line pharmacologic treatment for type 2 diabetes worldwide. It works primarily by activating AMPK in the liver, suppressing hepatic glucose production, while also improving peripheral insulin sensitivity — without stimulating insulin secretion and therefore without causing hypoglycemia as monotherapy. Common side effects include nausea, diarrhea, stomach cramps, and metallic taste, which are usually transient. It carries an FDA black box warning for lactic acidosis — a rare but potentially fatal complication occurring almost exclusively in patients with severe renal impairment (eGFR below 30) or serious comorbid illness.
Metformin
Uses & Why It's First-Line
Metformin is the first-line pharmacologic treatment for type 2 diabetes mellitus (T2DM) according to guidelines from the American Diabetes Association, the European Association for the Study of Diabetes, and most major endocrinology bodies worldwide. This consensus position reflects a combination of attributes no other single antidiabetic agent matches: robust glucose-lowering efficacy (typically 1–2% reduction in HbA1c), a strong safety record spanning six decades, weight neutrality or modest weight loss, absence of hypoglycemia risk as monotherapy, cardiovascular protective effects demonstrated in the UKPDS trial, and very low cost as a generic medication.
Beyond T2DM, metformin is used off-label in polycystic ovary syndrome (PCOS) to improve insulin sensitivity and restore menstrual regularity, in prediabetes to slow progression to T2DM, and in some protocols for gestational diabetes when insulin is declined or unavailable.
How It Works
Metformin's primary mechanism is activation of AMP-activated protein kinase (AMPK) in hepatocytes. AMPK acts as a cellular energy sensor; when activated, it inhibits mTOR and reduces expression of gluconeogenic enzymes including PEPCK (phosphoenolpyruvate carboxykinase) and G6Pase (glucose-6-phosphatase). The result is a dramatic reduction in hepatic glucose output — in T2DM, excess hepatic gluconeogenesis accounts for much of the fasting hyperglycemia, so targeting this process produces meaningful glucose lowering without stimulating insulin release.
Metformin also improves peripheral insulin sensitivity — muscle and fat cells respond better to existing insulin, enhancing glucose uptake. A third mechanism involves the gut: metformin slows intestinal glucose absorption and favorably alters the gut microbiome, effects that may contribute to its overall glycemic benefit and possibly to its GI side effects.
Unlike sulfonylureas or insulin, metformin does not stimulate pancreatic insulin secretion. This is why it does not cause hypoglycemia when used as monotherapy — glucose lowering is proportional to the degree of hyperglycemia present, not driven by a fixed insulin surge.
FDA BLACK BOX WARNING: Lactic acidosis — a rare but potentially fatal complication. Metformin accumulates when renal clearance is impaired, inhibiting mitochondrial respiration and causing lactate buildup. Risk factors include eGFR <30 mL/min (contraindicated), acute illness causing dehydration or hypoxia, excessive alcohol consumption, liver failure, and use of iodinated contrast dye. Symptoms: muscle pain, weakness, difficulty breathing, unusual sleepiness, abdominal discomfort. Seek emergency care immediately.
Side Effects
Common
- Nausea, vomiting, diarrhea, stomach cramps — occur in up to 30% initially; usually transient and dose-related
- Metallic taste — reported by some patients, typically mild
- Decreased appetite — actually a beneficial side effect for many
Serious
- Lactic acidosis — rare (<10 cases per 100,000 patient-years) but has ~50% mortality if untreated. Risk is almost exclusively in patients with the contraindicated conditions listed above.
- Vitamin B12 deficiency — metformin reduces intestinal absorption of B12 by interfering with the calcium-dependent ileal membrane transporter. After 4+ years of use, up to 30% of patients have subnormal B12 levels. Annual B12 monitoring is recommended in long-term users; supplementation is often warranted, especially if neuropathy develops.
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Iodinated Contrast Dye | Contrast can cause acute kidney injury; reduced renal clearance raises metformin levels and lactic acidosis risk. Guidelines recommend holding metformin at the time of contrast administration and for 48 hours after, restarting only when renal function is confirmed normal. | High — standard protocol to hold metformin pericontrast |
| Alcohol (excessive) | Alcohol potentiates metformin's effect on lactate metabolism and can cause hypoglycemia in poorly nourished patients. Binge drinking significantly raises lactic acidosis risk. | Moderate-High — moderate alcohol is acceptable; heavy/binge drinking is contraindicated |
| Topiramate | Topiramate inhibits carbonic anhydrase, which can reduce renal bicarbonate and lower blood pH (metabolic acidosis). Combined with metformin, risk of lactic acidosis is theoretically increased. | Moderate — monitor for signs of acidosis; both lower weight which may be beneficial otherwise |
| Cimetidine | Cimetidine (H2 blocker) inhibits renal tubular secretion of metformin via OCT2 transporters, increasing metformin plasma levels by up to 40%. | Moderate — other H2 blockers (famotidine, ranitidine) do not share this interaction; prefer alternatives |
| Furosemide (loop diuretics) | Furosemide increases metformin plasma levels; metformin may reduce furosemide clearance. Dehydration from aggressive diuresis also raises lactic acidosis risk in susceptible patients. | Moderate — monitor renal function and hydration status |
| Corticosteroids | Steroids raise blood glucose by increasing insulin resistance and hepatic gluconeogenesis, directly opposing metformin's mechanism. Glucose control often deteriorates significantly during steroid courses. | Moderate — may require insulin augmentation during steroid therapy; monitor glucose closely |
Warnings & Contraindications
Contraindications
- eGFR <30 mL/min/1.73 m² (severe renal impairment) — metformin cannot be adequately cleared
- Active liver disease or hepatic impairment — impairs lactate metabolism
- Metabolic acidosis, including diabetic ketoacidosis
- Allergy to metformin
Hold Metformin Before
- Iodinated contrast procedures — hold at time of procedure, restart 48 hrs later after confirming normal renal function
- Major surgery — hold the day of surgery due to NPO status and hemodynamic instability risk
- Acute illness causing dehydration, hypoxia, or hemodynamic instability
Learn about metformin's side effect profile in depth and how to manage them.
Explore Side Effects Guide →Frequently Asked Questions
Does metformin cause hypoglycemia (low blood sugar)?
No — not when used as monotherapy. Because metformin does not stimulate insulin secretion, it lowers blood glucose only when glucose is elevated (by suppressing hepatic glucose production and improving insulin sensitivity). Blood sugar cannot be driven below normal by this mechanism alone. Hypoglycemia can occur when metformin is combined with insulin or insulin secretagogues (like glipizide), but the risk comes from those drugs, not metformin.
Can I drink alcohol while taking metformin?
Moderate alcohol consumption (1–2 drinks on a given occasion, not daily drinking) is generally acceptable. The concern is with heavy or binge drinking: alcohol inhibits gluconeogenesis (mimicking and compounding metformin's primary mechanism), can cause hypoglycemia in fasted or malnourished states, and potentiates the lactic acidosis risk by impairing hepatic lactate metabolism. Patients should be advised to eat when drinking and to avoid intoxication.
Will I need to take metformin forever?
Type 2 diabetes is a progressive condition in most patients, and metformin addresses the underlying insulin resistance and hepatic glucose overproduction that persist with the disease. However, meaningful lifestyle changes — substantial weight loss (7–10% of body weight), sustained aerobic exercise, and improved diet — can improve insulin sensitivity to the point where some patients achieve normal glucose control without medication. This is more achievable early in the disease course. The decision to deprescribe should be guided by sustained HbA1c improvement and regular monitoring, not a fixed timeline.